The NCCN 2014 Nursing Program Webinar Series: Advancing Oncology Nursing Live Webinar Series will provide the oncology nurse with comprehensive and clinically relevant information regarding the management of patients with cancer.

The NCCN 2014 Nursing Program Webinar Series: Advancing Oncology Nursing Live Webinar Series will provide the oncology nurse with comprehensive and clinically relevant information regarding the management of patients with cancer.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.

Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.

Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.